New progress in iron chelation therapy

Research output: Contribution to journalArticle

Abstract

Iron is required for many enzymes which are critical for cellular functions and plays an important role in oxygen carrying proteins, e.g. hemoglobin. But it can be toxic when present in excess. Therefore, the total body iron store should be kept within defined limits. When there is excess of iron in the body, it is called iron overload. If it is untreated, it will damage the target organs, including the heart, liver and endocrine organs. Clinically we can use phlebotomy or iron chelators to treat iron overload. In the past 3 or 4 decades, only one available iron chelator "deferoxamine" can be used. However, poor compliances and inconvenience are major problems. During the past few years the advances on iron chelation research has been impressive, leading to the development of new oral iron chelators including deferiprone and deferasirox. The new treatment options greatly enhance the efficacy of iron chelation for preventing and treating the iron overload complications. Whichever iron chelator is chosen, patients should be closely monitored both for effectiveness of therapy and for toxic side effects.

Original languageEnglish
Pages (from-to)48-57
Number of pages10
JournalJournal of Internal Medicine of Taiwan
Volume20
Issue number1
Publication statusPublished - 2009 Feb 1

Fingerprint

Chelation Therapy
Iron
Chelating Agents
Iron Overload
Poisons
Deferoxamine
Phlebotomy
Hemoglobins
Oxygen

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{ffd3e150f79c4921b962d8d4c57759b2,
title = "New progress in iron chelation therapy",
abstract = "Iron is required for many enzymes which are critical for cellular functions and plays an important role in oxygen carrying proteins, e.g. hemoglobin. But it can be toxic when present in excess. Therefore, the total body iron store should be kept within defined limits. When there is excess of iron in the body, it is called iron overload. If it is untreated, it will damage the target organs, including the heart, liver and endocrine organs. Clinically we can use phlebotomy or iron chelators to treat iron overload. In the past 3 or 4 decades, only one available iron chelator {"}deferoxamine{"} can be used. However, poor compliances and inconvenience are major problems. During the past few years the advances on iron chelation research has been impressive, leading to the development of new oral iron chelators including deferiprone and deferasirox. The new treatment options greatly enhance the efficacy of iron chelation for preventing and treating the iron overload complications. Whichever iron chelator is chosen, patients should be closely monitored both for effectiveness of therapy and for toxic side effects.",
author = "Ya-Ping Chen and Wu, {Hung Chang} and Yu-Min Yeh and Chang, {Kwang Yu} and Wei-Hsin Chiu and Wen-Pin Su and Peng-Chan Lin and Chia-Jui Yen and Wu-Chou Su and Tsai-Yun Chen",
year = "2009",
month = "2",
day = "1",
language = "English",
volume = "20",
pages = "48--57",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "Society of Internal Medicine of Taiwan",
number = "1",

}

New progress in iron chelation therapy. / Chen, Ya-Ping; Wu, Hung Chang; Yeh, Yu-Min; Chang, Kwang Yu; Chiu, Wei-Hsin; Su, Wen-Pin; Lin, Peng-Chan; Yen, Chia-Jui; Su, Wu-Chou; Chen, Tsai-Yun.

In: Journal of Internal Medicine of Taiwan, Vol. 20, No. 1, 01.02.2009, p. 48-57.

Research output: Contribution to journalArticle

TY - JOUR

T1 - New progress in iron chelation therapy

AU - Chen, Ya-Ping

AU - Wu, Hung Chang

AU - Yeh, Yu-Min

AU - Chang, Kwang Yu

AU - Chiu, Wei-Hsin

AU - Su, Wen-Pin

AU - Lin, Peng-Chan

AU - Yen, Chia-Jui

AU - Su, Wu-Chou

AU - Chen, Tsai-Yun

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Iron is required for many enzymes which are critical for cellular functions and plays an important role in oxygen carrying proteins, e.g. hemoglobin. But it can be toxic when present in excess. Therefore, the total body iron store should be kept within defined limits. When there is excess of iron in the body, it is called iron overload. If it is untreated, it will damage the target organs, including the heart, liver and endocrine organs. Clinically we can use phlebotomy or iron chelators to treat iron overload. In the past 3 or 4 decades, only one available iron chelator "deferoxamine" can be used. However, poor compliances and inconvenience are major problems. During the past few years the advances on iron chelation research has been impressive, leading to the development of new oral iron chelators including deferiprone and deferasirox. The new treatment options greatly enhance the efficacy of iron chelation for preventing and treating the iron overload complications. Whichever iron chelator is chosen, patients should be closely monitored both for effectiveness of therapy and for toxic side effects.

AB - Iron is required for many enzymes which are critical for cellular functions and plays an important role in oxygen carrying proteins, e.g. hemoglobin. But it can be toxic when present in excess. Therefore, the total body iron store should be kept within defined limits. When there is excess of iron in the body, it is called iron overload. If it is untreated, it will damage the target organs, including the heart, liver and endocrine organs. Clinically we can use phlebotomy or iron chelators to treat iron overload. In the past 3 or 4 decades, only one available iron chelator "deferoxamine" can be used. However, poor compliances and inconvenience are major problems. During the past few years the advances on iron chelation research has been impressive, leading to the development of new oral iron chelators including deferiprone and deferasirox. The new treatment options greatly enhance the efficacy of iron chelation for preventing and treating the iron overload complications. Whichever iron chelator is chosen, patients should be closely monitored both for effectiveness of therapy and for toxic side effects.

UR - http://www.scopus.com/inward/record.url?scp=63049100818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049100818&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:63049100818

VL - 20

SP - 48

EP - 57

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 1

ER -